Treatment for neoplastic diseases

ABSTRACT

Administration of a mAb that specifically binds IL-1α is useful for treating tumor-associated diseases in human subjects.

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a continuation application of U.S.nonprovisional patent application Ser. No. 13/215,464 filed on Aug. 23,2011, which claims the priority of U.S. provisional patent applicationserial Nos. 61/376,097 filed on Aug. 23, 2010, 61/406,759 filed on Oct.26, 2010, 61/411,183 filed on Nov. 8, 2010, and 61/480,635 filed on Apr.29, 2011, all of which are incorporated herein by reference in theirentirety.

STATEMENT AS TO FEDERALLY SPONSORED RESEARCH

Not applicable.

FIELD OF THE INVENTION

The invention relates generally to the fields of medicine, oncology, andimmunology. More particularly, the invention relates to the use ofantibodies (Abs) which specifically bind interleukin-1α (IL-1α) to treata tumor-associated disease and other tumor-associated pathologies.

BACKGROUND

Despite many advances, tumor-associated diseases such as cancer remainone of the leading causes of death and morbidity in developed nations.Although many of the molecular mechanisms of tumorigenesis have now beenrevealed, standard treatment of most aggressive tumors continues to besurgical resection, chemotherapy, and radiotherapy. While increasinglysuccessful, each of these treatments still causes numerous undesiredside effects. For example, surgery results in pain, traumatic injury tohealthy tissue, and scarring. Radiotherapy and chemotherapy causenausea, immune suppression, gastric ulceration, and secondarytumorigenesis.

Over the last several years much progress has been made using biologicagents such as Abs to treat cancerous tumors. Abs can directly targetspecific types of tumor cells to harness a patient's immune response tokill the tumor. Alternatively, they can target cell growth factors tointerfere with the growth of tumor cells. As with conventionalchemotherapeutic agents, not all anti-tumor Abs are useful for treatingall types of neoplasms, and many initially effective antibodies laterlose potency. Thus new anti-tumor Abs are needed.

SUMMARY

The invention is based on the discovery that a mAb that specificallybinds IL-1α is useful for treating various tumor-associated diseases.

Accordingly, the invention features a medicament and method for treatingneoplastic diseases (e.g., a colorectal cancer such as one having a KRASmutation, an EBV-associated cancer such as nasopharygeal carcinoma orBurkitt's lymphoma, non-small cell lung cancer (NSCLC) or non-cancerousconditions associated with tumors such as Castleman's disease) in ahuman subject. The method can be performed by administering to thesubject a pharmaceutical composition including a pharmaceuticallyacceptable carrier and an amount of an anti-IL-1a Ab effective toameliorate a symptom of a tumor-associated pathology and/or to reducethe size of a tumor in the subject by at least about 10% (e.g., at least8, 9, 10, 15, 17, 20, 30, 40, 50, 60, 70, 80, 90, or 100%). Themedicament can include an anti-IL-1a Ab. The anti-IL-1a Ab can be a mAbsuch as an IgG1. The anti-IL-1a Ab can be the mAb designated as MABp1 ora mAb that includes one or more complementarity determining regions(CDRs) of MABp1.

The pharmaceutical composition can be administered to the subject byinjection, subcutaneously, intravenously, intramuscularly, or directlyinto a tumor. In the method, the dose can be at least 0.25 (e.g., atleast 0.2, 0.5, 0.75, 1, 2, 3, 4, or 5) mg/ml.

Unless otherwise defined, all technical terms used herein have the samemeaning as commonly understood by one of ordinary skill in the art towhich this invention belongs. Commonly understood definitions ofbiological terms can be found in Rieger et al., Glossary of Genetics:Classical and Molecular, 5th edition, Springer-Verlag: New York, 1991;and Lewin, Genes V, Oxford University Press: New York, 1994. Commonlyunderstood definitions of medical terms can be found in Stedman'sMedical Dictionary, 27th Edition, Lippincott, Williams & Wilkins, 2000.

As used herein, an “Ab” or “Ab” is an immunoglobulin (Ig), a solution ofidentical or heterogeneous Igs, or a mixture of Igs. An “Ab” can alsorefer to fragments and engineered versions of Igs such as Fab, Fab′, andF(ab′)₂ fragments; and scFv's, heteroconjugate Abs, and similarartificial molecules that employ Ig-derived CDRs to impart antigenspecificity. A “mAb” or “mAb” is an Ab expressed by one clonal B cellline or a population of Ab molecules that contains only one species ofan antigen binding site capable of immunoreacting with a particularepitope of a particular antigen. A “polyclonal Ab” or “polyclonal Ab” isa mixture of heterogeneous Abs. Typically, a polyclonal Ab will includemyriad different Ab molecules which bind a particular antigen with atleast some of the different Abs immunoreacting with a different epitopeof the antigen. As used herein, a polyclonal Ab can be a mixture of twoor more mAbs.

An “antigen-binding portion” of an Ab is contained within the variableregion of the Fab portion of an Ab and is the portion of the Ab thatconfers antigen specificity to the Ab (i.e., typically thethree-dimensional pocket formed by the CDRs of the heavy and lightchains of the Ab). A “Fab portion” or “Fab region” is the proteolyticfragment of a papain-digested Ig that contains the antigen-bindingportion of that Ig. A “non-Fab portion” is that portion of an Ab notwithin the Fab portion, e.g., an “Fc portion” or “Fc region.” A“constant region” of an Ab is that portion of the Ab outside of thevariable region. Generally encompassed within the constant region is the“effector portion” of an Ab, which is the portion of an Ab that isresponsible for binding other immune system components that facilitatethe immune response. Thus, for example, the site on an Ab that bindscomplement components or Fc receptors (not via its antigen-bindingportion) is an effector portion of that Ab.

When referring to a protein molecule such as an Ab, “purified” meansseparated from components that naturally accompany such molecules.Typically, an Ab or protein is purified when it is at least about 10%(e.g., 9%, 10%, 20%, 30% 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%,99.9%, and 100%), by weight, free from the non-Ab proteins or othernaturally-occurring organic molecules with which it is naturallyassociated. Purity can be measured by any appropriate method, e.g.,column chromatography, polyacrylamide gel electrophoresis, or HPLCanalysis. A chemically-synthesized protein or other recombinant proteinproduced in a cell type other than the cell type in which it naturallyoccurs is “purified.”

By “bind”, “binds”, or “reacts with” is meant that one moleculerecognizes and adheres to a particular second molecule in a sample, butdoes not substantially recognize or adhere to other molecules in thesample. Generally, an Ab that “specifically binds” another molecule hasa K_(d) greater than about 10⁵, 10⁶, 10⁷, 10⁸, 10⁹, 10¹⁰, 10¹¹, or 10¹²liters/mole for that other molecule.

A “therapeutically effective amount” is an amount which is capable ofproducing a medically desirable effect in a treated animal or human(e.g., amelioration or prevention of a disease or symptom of a disease).

Although methods and materials similar or equivalent to those describedherein can be used in the practice or testing of the present invention,suitable methods and materials are described below. All publicationsmentioned herein are incorporated by reference in their entirety. In thecase of conflict, the present specification, including definitions willcontrol. In addition, the particular embodiments discussed below areillustrative only and not intended to be limiting.

DETAILED DESCRIPTION

The invention encompasses compositions and methods for ameliorating oneor more symptoms of a tumor-associated pathology in a subject. The belowdescribed preferred embodiments illustrate adaptation of thesecompositions and methods. Nonetheless, from the description of theseembodiments, other aspects of the invention can be made and/or practicedbased on the description provided below.

General Methodology

Methods involving conventional immunological and molecular biologicaltechniques are described herein Immunological methods (for example,assays for detection and localization of antigen-Ab complexes,immunoprecipitation, immunoblotting, and the like) are generally knownin the art and described in methodology treatises such as CurrentProtocols in Immunology, Coligan et al., ed., John Wiley & Sons, NewYork. Techniques of molecular biology are described in detail intreatises such as Molecular Cloning: A Laboratory Manual, 2nd ed., vol.1-3, Sambrook et al., ed., Cold Spring Harbor Laboratory Press, ColdSpring Harbor, N.Y., 2001; and Current Protocols in Molecular Biology,Ausubel et al., ed., Greene Publishing and Wiley-Interscience, New York.Ab methods are described in Handbook of Therapeutic Abs, Dubel, S., ed.,Wiley-VCH, 2007. General methods of medical treatment are described inMcPhee and Papadakis, Current Medical Diagnosis and Treatment 2010,49^(th) Edition, McGraw-Hill Medical, 2010; and Fauci et al., Harrison'sPrinciples of Internal Medicine, 17^(th) Edition, McGraw-HillProfessional, 2008

Treatment of a Tumor-associated Disease

The compositions and methods described herein are useful for treating atumor-associated disease in a mammalian subject by administering to thesubject a pharmaceutical composition including an amount of ananti-IL-1α Ab effective to improve at least one characteristic of thetumor-associated disease in the subject. The mammalian subject might beany that suffers from a tumor-associated disease including, humanbeings, dogs, cats, horses, cattle, sheep, goats, and pigs. Humansubjects might be male, female, adults, children, seniors (65 andolder), and those with other diseases. Particularly preferred subjectsare those whose disease has progressed after treatment withchemotherapy, radiotherapy, surgery, and/or biologic agents. Any type ofa tumor-associated disease susceptible to treatment with an anti-IL-1αAb might be targeted. Anti-IL-1α Ab administration is thought to beparticularly effective for treating colorectal tumors (e.g., colorectalcancers with a KRAS mutation), EBV-associated neoplasms such asnasopharyngeal cancer or Burkitt's lymphoma, NSCLC, and blood cellneoplasms such as in Castleman's disease. A disease with tumorsexpressing IL-1α or tumors infiltrated with IL-1α inflammatory cellsmight also be targeted. The particular characteristic of atumor-associated disease to be improved can be tumor size (e.g., TO,Tis, or T1-4), state of metastasis (e.g., M0, M1), number of observabletumors, node involvement (e.g., NO, N1-4, Nx), grade (i.e., grades 1, 2,3, or 4), stage (e.g., 0, I, II, III, or IV), presence or concentrationof certain markers on the cells or in bodily fluids (e.g., AFP, B2M,beta-HCG, BTA, CA 15-3, CA 27.29, CA 125, CA 72.4, CA 19-9, calcitonin,CEA, chromgrainin A, EGFR, hormone receptors, HER2, HCG,immunoglobulins, NSE, NMP22, PSA, PAP, PSMA, S-100, TA-90, andthyroglobulin), and/or associated pathologies (e.g., ascites or edema)or symptoms (e.g., cachexia, fever, anorexia, or pain). The improvement,if measureable by percent, can be at least 5, 10, 15, 20, 25, 30, 40,50, 60, 70, 80, or 90% (e.g., volume or linear dimensions of a tumor).

Antibodies and Other Agents that Target IL-1α

Any suitable type of Ab or other biologic agent (e.g., a fusion proteinincluding an IL-1α-binding component such as an IL-1 receptor) thatspecifically binds IL-1α and reduces a characteristic of atumor-associated disease in a subject might be used in the invention.For example, the anti-IL-1α Ab used might be mAb, a polyclonal Ab, amixture of mAbs, or an Ab fragment or engineered Ab-like molecule suchas an scFv. The Ka of the Ab is preferably at least 1×10⁹ M¹ or greater(e.g., greater than 9×10¹⁰ M⁻¹, 8×10¹⁰ M⁻¹, 7×10¹⁰ M⁻¹, 6×10¹⁰ M⁻¹,5×10¹⁰ M⁻¹, 4×10¹⁰ M⁻¹, 3×10¹⁰ M⁻¹, 2×10¹⁰ M⁻¹, or 1×10¹⁰ M⁻¹). In apreferred embodiment, the invention utilizes a fully human mAb thatincludes (i) an antigen-binding variable region that exhibits very highbinding affinity (e.g., at least nano or picomolar) for human IL-1α and(ii) a constant region. The human Ab is preferably an IgG1, although itmight be of a different isotype such as IgM, IgA, or IgE, or subclasssuch as IgG2, IgG3, or IgG4. One example of a particularly useful mAb isMABp1, an IL-1α-specific IgG1 mAb described in U.S. patent applicationSer. No. 12/455,458 filed on Jun. 1, 2009. Other useful mAbs are thosethat include at least one but preferably all the CDRs of MABp1.

Because B lymphocytes which express Ig specific for human IL-1α occurnaturally in human beings, a presently preferred method for raising mAbsis to first isolate such a B lymphocyte from a subject and thenimmortalize it so that it can be continuously replicated in culture.Subjects lacking large numbers of naturally occurring B lymphocyteswhich express Ig specific for human IL-1α may be immunized with one ormore human IL-1α antigens to increase the number of such B lymphocytes.Human mAbs are prepared by immortalizing a human Ab secreting cell(e.g., a human plasma cell). See, e.g., U.S. Pat. No. 4,634,664.

In an exemplary method, one or more (e.g., 5, 10, 25, 50, 100, 1000, ormore) human subjects are screened for the presence of such humanIL-1α-specific Ab in their blood. Those subjects that express thedesired Ab can then be used as B lymphocyte donors. In one possiblemethod, peripheral blood is obtained from a human donor that possesses Blymphocytes that express human IL-1α-specific Ab. Such B lymphocytes arethen isolated from the blood sample, e.g., by cells sorting (e.g.,fluorescence activated cell sorting, “FACS”; or magnetic bead cellsorting) to select B lymphocytes expressing human IL-1α-specific Ig.These cells can then be immortalized by viral transformation (e.g.,using EBV) or by fusion to another immortalized cell such as a humanmyeloma according to known techniques. The B lymphocytes within thispopulation that express Ig specific for human IL-1α can then be isolatedby limiting dilution methods (e.g., cells in wells of a microtiter platethat are positive for Ig specific for human IL-1α are selected andsubcultured, and the process repeated until a desired clonal line can beisolated). See, e.g., Goding, MAbs: Principles and Practice, pp. 59-103,Academic Press, 1986. Those clonal cell lines that express Ig having atleast nanomolar or picomolar binding affinities for human IL-1α arepreferred. MAbs secreted by these clonal cell lines can be purified fromthe culture medium or a bodily fluid (e.g., ascites) by conventional Igpurification procedures such as salt cuts, size exclusion, ion exchangeseparation, and affinity chromatography.

Although immortalized B lymphocytes might be used in in vitro culturesto directly produce mAbs, in certain cases it might be desirable to useheterologous expression systems to produce mAbs. See, e.g., the methodsdescribed in U.S. patent application Ser. No. 11/754,899. For example,the genes encoding an mAb specific for human IL-1α might be cloned andintroduced into an expression vector (e.g., a plasmid-based expressionvector) for expression in a heterologous host cell (e.g., CHO cells, COScells, myeloma cells, and E. coli cells). Because Igs include heavy (H)and light (L) chains in an H₂L₂ configuration, the genes encoding eachmay be separately isolated and expressed in different vectors.

Although generally less preferred due to the greater likelihood that asubject will develop an anti-Ab response, chimeric mAbs (e.g.,“humanized” mAbs), which are antigen-binding molecules having differentportions derived from different animal species (e.g., variable region ofa mouse Ig fused to the constant region of a human Ig), might be used inthe invention. Such chimeric Abs can be prepared by methods known in theart. See, e.g., Morrison et al., Proc. Nat'l. Acad. Sci. USA, 81:6851,1984; Neuberger et al., Nature, 312:604, 1984; Takeda et al., Nature,314:452, 1984. Similarly, Abs can be humanized by methods known in theart. For example, mAbs with a desired binding specificity can behumanized by various vendors or as described in U.S. Pat. Nos.5,693,762; 5,530,101; or 5,585,089.

The mAbs described herein might be affinity matured to enhance orotherwise alter their binding specificity by known methods such as VHand VL domain shuffling (Marks et al. Bio/Technology 10:779-783, 1992),random mutagenesis of the hypervariable regions (HVRs) and/or frameworkresidues (Barbas et al. Proc Nat. Acad. Sci. USA 91:3809-3813, 1994;Schier et al. Gene 169:147-155, 1995; Yelton et al. J. Immunol.155:1994-2004, 1995; Jackson et al., J. Immunol. 154(7):3310-9, 1995;and Hawkins et al, J. Mol. Biol. 226:889-896, 1992. Amino acid sequencevariants of an Ab may be prepared by introducing appropriate changesinto the nucleotide sequence encoding the Ab. In addition, modificationsto nucleic acid sequences encoding mAbs might be altered (e.g., withoutchanging the amino acid sequence of the mAb) for enhancing production ofthe mAb in certain expression systems (e.g., intron elimination and/orcodon optimization for a given expression system). The mAbs describedherein can also be modified by conjugation to another protein (e.g.,another mAb) or non-protein molecule. For example, a mAb might beconjugated to a water soluble polymer such as polyethylene glycol or acarbon nanotube (See, e.g., Kam et al., Proc. Natl. Acad. Sci. USA 102:11600-11605, 2005). See, U.S. patent application Ser. No. 11/754,899.

Preferably, to ensure that high titers of human IL-1α-specific mAb canbe administered to a subject with minimal adverse effects, the mAbcompositions of the invention are at least 0.5, 1, 2, 3, 4, 5, 6, 7, 8,9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90,95, 96, 97, 98, 99, 99.9 or more percent by weight pure (excluding anyexcipients). The mAb compositions of the invention might include only asingle type of mAb (i.e., one produced from a single clonal B lymphocyteline) or might include a mixture of two or more (e.g., 2, 3, 4, 5, 6, 7,8, 9, 10 or more) different types of mAbs.

To modify or enhance their function, the human IL-1α mAbs might beconjugated with another molecule such as a cytotoxin. A human IL-1αspecific mAb might be conjugated with one or more cytotoxins to moreeffectively kill cells expressing IL-1α. Cytotoxins for use in theinvention can be any cytotoxic agent (e.g., molecule that can kill acell after contacting the cell) that can be conjugated to a human IL-1αspecific mAb. Examples of cytotoxins include, without limitation,radionuclides (e.g., ³⁵S, ¹⁴C, ³²P, ¹²⁵I, ¹³¹I, ⁹⁰Y, ⁸⁹Zr, ²⁰¹Tl, ¹⁸⁶Re,¹⁸⁸Re, ⁵⁷Cu, ²¹³Bi, and ²¹¹At), conjugated radionuclides, andchemotherapeutic agents. Further examples of cytotoxins include, but arenot limited to, antimetabolites (e.g., 5-fluorouricil (5-FU),methotrexate (MTX), fludarabine, etc.), anti-microtubule agents (e.g.,vincristine, vinblastine, colchicine, taxanes (such as paclitaxel anddocetaxel), etc.), alkylating agents (e.g., cyclophasphamide, melphalan,bischloroethylnitrosurea (BCNU), etc.), platinum agents (e.g., cisplatin(also termed cDDP), carboplatin, oxaliplatin, JM-216, CI-973, etc.),anthracyclines (e.g., doxorubicin, daunorubicin, etc.), antibioticagents (e.g., mitomycin-C), topoisomerase inhibitors (e.g., etoposide,tenoposide, and camptothecins), or other cytotoxic agents such as ricin,diptheria toxin (DT), Pseudomonas exotoxin (PE) A, PE40, abrin, saporin,pokeweed viral protein, ethidium bromide, glucocorticoid, anthrax toxinand others. See, e.g., U.S. Pat. No. 5,932,188.

While the IL-1α specific Abs described above are preferred for use inthe invention, in some cases, other agents that specifically targetIL-1α might be used so long as their administration leads to improvementof a characteristic of a tumor-associated disease. These other agentsmight include small organic molecules, aptamers, peptides, and proteinsthat specifically bind IL-1α (e.g., anakinra or rilonacept).

Pharmaceutical Compositions and Methods

The anti-IL-1α Ab compositions may be administered to animals or humansin pharmaceutically acceptable carriers (e.g., sterile saline), that areselected on the basis of mode and route of administration and standardpharmaceutical practice. A list of pharmaceutically acceptable carriers,as well as pharmaceutical formulations, can be found in Remington'sPharmaceutical Sciences, a standard text in this field, and in USP/NF.Other substances may be added to the compositions and other steps takento stabilize and/or preserve the compositions, and/or to facilitatetheir administration to a subject.

For example, the Ab compositions might be lyophilized (see Draber etal., J. Immunol. Methods. 181:37, 1995; and PCT/US90/01383); dissolvedin a solution including sodium and chloride ions; dissolved in asolution including one or more stabilizing agents such as albumin,glucose, maltose, sucrose, sorbitol, polyethylene glycol, and glycine;filtered (e.g., using a 0.45 and/or 0.2 micron filter); contacted withbeta-propiolactone; and/or dissolved in a solution including amicrobicide (e.g., a detergent, an organic solvent, and a mixture of adetergent and organic solvent.

The Ab compositions may be administered to animals or humans by anysuitable technique. Typically, such administration will be parenteral(e.g., intravenous, subcutaneous, intramuscular, or intraperitonealintroduction). The compositions may also be administered directly to thetarget site (e.g., intratumorally) by, for example, injection. Othermethods of delivery, e.g., liposomal delivery or diffusion from a deviceimpregnated with the composition, are known in the art. The compositionmay be administered in a single bolus, multiple injections, or bycontinuous infusion (e.g., intravenously or by peritoneal dialysis).

A therapeutically effective amount is an amount which is capable ofproducing a medically desirable result in a treated animal or human. Aneffective amount of anti-IL-1α Ab compositions is an amount which showsclinical efficacy in patients as measured by the improvement in one ormore a tumor-associated disease characteristics described above. As iswell known in the medical arts, dosage for any one animal or humandepends on many factors, including the subject's size, body surfacearea, age, the particular composition to be administered, sex, time androute of administration, general health, and other drugs beingadministered concurrently. Preferred doses range from about 0.2 to 20(e.g., 0.15, 0.2, 0.3, 0.4, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20,30, 50, or 100) mg/kg body weight. The dose may be given repeatedly,e.g., hourly, daily, semi-weekly, weekly, bi-weekly, tri-weekly, ormonthly.

EXAMPLES Example 1—Xilonix™

Xilonix™ is a sterile injectable liquid formulation of 15 mg/mL MABp1 ina stabilizing isotonic buffer (pH 6.4). Each 10-mL Type I borosilicateglass serum vial contains 5 mL of the formulation, and is sealed with a20-mm Daikyo Flurotec butyl rubber stopper and flip-off aluminum seal.The product is stored at 5±3° C., with excursions to room temperaturepermitted. The exact composition of the drug product is shown below:

Composition of the Drug Product (Xilonix ™) Ingredient GradeManufacturer Concentration MABp1 Ab GMP XBiotech 15 mg/mL sodiumphosphate dibasic compendial JT Baker 12 mg/mL citric acid monohydratecompendial JT Baker 2 mg/mL Trehalose•2H2O (high- compendial Ferro- 60mg/mL purity low endotoxin) Pfanstiehl polysorbate 80 compendial JTBaker 0.2 mg/mL Phosphoric acid, to compendial JT Baker 0.04 mg/mLadjust pH water for injection compendial Microbix q.s.

Method of Administration:

The calculated volume is withdrawn from the drug (mAb)-containingvial(s) using a suitable syringe. The drug is then injected into a smallIV bag containing 100 mL of normal saline (0.9% NaCl) and mixed byinversion. The diluted drug product can be stored at room temperaturefor 3 hours prior to administration and is infused over a 1-hour period,with the subject being monitored for signs of an infusion reaction. Theinfusion is chased with a minimum of 30 mLs of normal saline to deliverany product that may be held up in the infusion set.

Example 2—Treatment of Colorectal Cancer with an IL-1α-Specific MAb(Xilonix™)

The human subject was a 63 year-old female diagnosed with metastaticcolorectal cancer (KRAS mutation positive). Prior to treatment withXilonix™, the subject underwent right hemicolectomy and was reportedlystaged T3N1MX. She thereafter received adjuvant chemotherapy with FOLFOXfor a total of 12 cycles over about six months. A PET CT scan performedabout two months after completion of FOLFOX revealed a mass in herpelvis. The subject was hospitalized at the time for placement ofureteral stent due to obstructive hydronephrosis apparently from thetumor. She started FOLFIRI and Avastin shortly thereafter and received 8cycles of therapy. The subject then underwent re-staging PET CT scanwhich confirmed disease in the pelvis, and also revealed small pulmonarynodules consistent with metastatic disease. A CT scan of the chest,abdomen and pelvis revealed a 12 cm pelvic mass, a 2 cm omental mass,and the hydronephrosis on the right side with associated ureteral stent.She received 2 extra cycles of FOLFIRI and Avastin. A subsequent PET CTscan showed progression of the bilateral pulmonary nodules. The subjectthen started irinotecan and Erbitux® (Cetuximab) therapy. A follow upPET CT scan demonstrated disease progression in the lungs.

The subject was initiated on a phase 1 trial with Doxil® (DoxorubicinLiposomal), Velcade® (Bortezomib), and Gemzar® (Gemcitabine) butunfortunately the first re-staging suggested disease progression. Shealso completed another phase 1 trial with oxaliplatin in combinationwith azacitydineon and completed 2 cycles before disease progression. Atthe conclusion of her participation on this last clinical phase 1 trial,the subject was enrolled in the current clinical trial.

She was enrolled in the first dosing cohort (0.25 mg/ml) and completed5-21 day cycles on the protocol, thus receiving a total of fiveinfusions of MABp1 (0.25 mg/kg) every 21 days. The subject's dose wasincreased to 0.75 mg/kg on Cycle 6 Day 1. An initial PET CT scanrevealed about a 17% reduction in the sum of diameters in the patient'stumors that were being tracked. Following additional doses of MABp1, anover 30% reduction in the sum of diameters in the patient's trackedtumors was observed. A Chest CT showed a paratrocheal lymph node thatpreviously measured 3.5 cm was reduced to 2.9 cm at the end of Cycle 6.A left lung metastasis decreased from 2.2 cm to 1.9 cm, and an implantfrom the left rectus muscle decreased from 3.2 cm to 2.7 cm. The CEAtumor marker at baseline was 81, decreased to 69.2 at the end of cycle3, and was 27.9 as of Cycle 7 Day 1. This patient has continued ontherapy for over 71 weeks and the disease has remained stable.

Example 3—Treatment of Nasopharygeal Cancer with an IL-1α-Specific MAb(Xilonix™)

The subject was a 47 year old Chinese male having EBV+(Epstein-Barrvirus) nasopharyngeal carcinoma with the histological subtypelymphoepithelioma (old terminology) or non-keratinizing carcinoma. Thesubject was previously treated with cisplatin, 5-FU, radiotherapy,Taxotere® (Docetaxel), Gemzar® (Gemcitabine), Xeloda® (Capecitabine),adoptive EBV-directed T cell transfer, and Cymevene® (Ganciclovir) incombination with Gemzar® (Gemcitabine). Prior to starting therapy, thepatient had fatigue, fevers and sweats, and was receiving frequenttherapeutic paracentesis for ascites.

The subject began MABp1 treatment on day 0 at 1.25 mg/kg IV every twoweeks. By days 3 and 4, a marked decrease in the subjects fatigue,fevers, and sweats was noted. The ascites also resolved. Abdominal CTabdomen scans showed a reduction in the size of a metastatic liver tumorfrom 50.4 mm on day 1 to 35.8 mm by day 36 (almost 30%) of one of themasses. Multiple other liver lesions decreased in size, and bone lesionsappeared to be stable.

Example 4—Treatment of Castleman's Syndrome with an IL-1α-Specific MAb(Xilonix™)

The subject was a 55-year-old woman suffering from Castleman's disease(the variant known as POEMS syndrome). Her symptoms included fatigue,edema, and nerve pain. Prior treatment with Rituxan® (Rituximab) and aninvestigational anti-IL-6 therapy failed. The subject was administered atotal of four infusions of MABp1 (0.75 mg/kg) every 21 days. Thesubject's dose was increased to 1.25 mg/kg in the next cycle.

This subject had stable disease through 2 re-stagings, and has beentreated for over 4 months. For approximately 2 weeks after eachinjection, her symptoms of fatigue, edema, and nerve pain improvedsignificantly, and then gradually recurred until the next injection. HerRECIST staging criteria showed 2% increase of lymph node size frombaseline at the first restage, and 4% increase of lymph node size frombaseline at the second restage.

After completing 7 cycles, the subject withdrew consent for therapy inorder to try another experimental treatment. After being off study for 8weeks, the subject physician requested that she be allowed to resumetherapy with MABp1 due to “rapid disease progression”. Since resumingtreatment, the subject's disease is stable and she has been on study forover 58 weeks.

Example 5—Treatment of NSCLC with an IL-1α-Specific MAb (Xilonix™)

The subject was an 84 year old female with a history of metastaticnon-small cell lung cancer diagnosed by fine needle aspiration. Threemonths after diagnosis, the subject began treatment with Tarceva®(Erlotinib) for 8 months at which point disease progression was noted.The subject was then treated with 11 cycles of Alimta® (Permetrexed)over 8 months, at which time treatment was halted due to the developmentof renal failure of undetermined etiology. Six months later, progressivedisease was noted and the patient was again treated with Tarceva®(Erlotinib) for 3 months. At that point, her CAT scan showed furtherprogressive disease in the lungs with an increase in size of a rightupper-lobe mass, pulmonary nodules consistent with metastases, andincreasing intra-thoracic adenopathy.

The subject was then enrolled in a trial using Xilonix™. MABp1 (3.75mg/kg) was infused intravenously every 21 days for 9 cycles. Aftertreatment, stable disease was noted for approximately 30 weeks, and inthe most recent restaging the right lung lesion appeared to becavitating.

Example 6—Treatment of Non-Small Cell Lung Cancer with an IL-1α-SpecificMAb (Xilonix™)

The subject was a 52 yr old female diagnosed with KRAS-positivenon-small cell (adenocarcinoma) cancer of the lung on day 0. A PET/CTscan from day 14 revealed a 4×3.5 cm left upper lobe mass, with diseasemetastasis to the lungs, hilar nodes, right inguinal nodes, rightadrenal, 4th right rib, and sacroiliac joint. The subject begantreatment with Carboplatin, Paclitaxel, and Bevacizumab a few weeksafter the scan. The subject had a good initial response and completedfive cycles before progressing at about 5 months from the firsttreatment. Over the next six months, the subject was treated with 3cycles of Docetaxel and one cycle of Carboplatin plus Pemetrexed.Despite this therapy, she continued to progress.

The subject subsequently began treatment with MABp1. After only 4 daysthe subject began experiencing a worsening of her headaches. These wereinitially attributed to sinusitis, but MRI revealed brain metastases.The investigator believed that these were likely present prior tobeginning therapy, however, the subject came off of study after only onedose of MABp1 to receive gamma-knife radiotherapy. The subject was seenin follow up twenty days after the initial MABp1 dose, and reported asubjective improvement in symptoms with a decrease in her chest pain.Because of this, the investigator checked a chest x-ray, which showed“an obvious decrease in the size of her lung lesions” after only onedose. A waiver was issued, and the subject resumed therapy. Forty-sixdays after the initial MABp1 dose, the subject underwent restaging, andhad a 6% decrease in the sum total diameter of lesions as graded byRECIST criteria.

Other Embodiments

It is to be understood that while the invention has been described inconjunction with the detailed description thereof, the foregoingdescription is intended to illustrate and not limit the scope of theinvention, which is defined by the scope of the appended claims. Otheraspects, advantages, and modifications are within the scope of thefollowing claims.

What is claimed is:
 1. A method of stabilizing a progressive cancer in ahuman patient having cancer that has progressed after treatment withchemotherapy, radiotherapy, or biologic agents, the method comprisingthe step of repeatedly administering to the subject a pharmaceuticalcomposition comprising a pharmaceutically acceptable carrier and ananti-interleukin-1alpha (anti-IL-1α) antibody at least until theprogression of the cancer has been stabilized.
 2. The method of claim 1,wherein the human patient's progressive cancer is metastatic, and thestep of repeatedly administering the pharmaceutical composition resultsin a decrease in the tumor burden in the patient.
 3. The method of claim1, wherein the progressive cancer is metastatic colorectal cancer. 4.The method of claim 2, wherein the progressive cancer is metastaticcolorectal cancer.
 5. The method of claim 1, wherein the progressivecancer is metastatic non-small cell lung cancer.
 6. The method of claim2, wherein the progressive cancer is metastatic non-small cell lungcancer.
 7. A method of reducing the size of a tumor in a human patientwith nasopharyngeal carcinoma that was previously treated withchemotherapy, radiotherapy, or biologic agents, the method comprisingthe step of repeatedly administering to the subject a pharmaceuticalcomposition comprising a pharmaceutically acceptable carrier and ananti-IL-1α antibody at least until the size of the tumor is reduced. 8.The method of claim 7, wherein the patient has at least one symptomselected from the group consisting of fatigue, fever, sweats, andascites, and the step of repeatedly administering the pharmaceuticalcomposition results in a decrease in the at least one symptom.
 9. Amethod of stabilizing Castleman's disease in a human patient, the methodcomprising the step of repeatedly administering to the subject apharmaceutical composition comprising a pharmaceutically acceptablecarrier and an anti-IL-1α antibody at least until the progression of theCastleman's disease has been stabilized.